Pathology Department, Hospital Universitari Joan XXIII, 43005 Tarragona, Spain.
Surgery Department, Programme of Surgery and Morphological Sciences, Universitat Autònoma de Barcelona (UAB), 08193 Barcelona, Spain.
Int J Mol Sci. 2023 May 12;24(10):8655. doi: 10.3390/ijms24108655.
Colitis-associated colorectal carcinoma (CAC) occurs in inflammatory bowel disease (IBD) because of the "chronic inflammation-dysplasia-cancer" carcinogenesis pathway characterized by p53 alterations in the early stages. Recently, gastric metaplasia (GM) has been described as the initial event of the serrated colorectal cancer (CRC) process, resulting from chronic stress on the colon mucosa. The aim of the study is to characterize CAC analyzing p53 alterations and microsatellite instability (MSI) to explore their relationship with GM using a series of CRC and the adjacent intestinal mucosa. Immunohistochemistry was performed to assess p53 alterations, MSI and MUC5AC expression as a surrogate for GM. The p53 mut-pattern was found in more than half of the CAC, most frequently stable (MSS) and MUC5AC negative. Only six tumors were unstable (MSI-H), being with p53 wt-pattern ( = 0.010) and MUC5AC positive ( = 0.005). MUC5AC staining was more frequently observed in intestinal mucosa, inflamed or with chronic changes, than in CAC, especially in those with p53 wt-pattern and MSS. Based on our results, we conclude that, as in the serrated pathway of CRC, in IBD GM occurs in inflamed mucosa, persists in those with chronic changes and disappears with the acquisition of p53 mutations.
结肠炎相关结直肠癌(CAC)发生于炎症性肠病(IBD)中,因为其具有“慢性炎症-异型增生-癌症”的癌变途径,这一途径的特征为早期 p53 改变。最近,胃化生(GM)被描述为锯齿状结直肠癌(CRC)进程的初始事件,这是由结肠黏膜的慢性应激引起的。本研究的目的是通过一系列 CRC 及其相邻肠黏膜来分析 p53 改变和微卫星不稳定性(MSI),以研究其与 GM 的关系。采用免疫组织化学法来评估 p53 改变、MSI 和 MUC5AC 表达,以作为 GM 的替代指标。在超过一半的 CAC 中发现了 p53 突变型,最常见的是稳定型(MSS)和 MUC5AC 阴性。只有 6 个肿瘤为不稳定型(MSI-H),且具有 p53 wt 型( = 0.010)和 MUC5AC 阳性( = 0.005)。MUC5AC 染色在炎症或慢性改变的肠黏膜中比在 CAC 中更频繁地被观察到,尤其是在具有 p53 wt 型和 MSS 的 CAC 中。根据我们的结果,我们得出结论,与 CRC 的锯齿状途径一样,在 IBD 中,GM 发生于炎症黏膜中,在具有慢性改变的患者中持续存在,而随着 p53 突变的获得而消失。